Skip to main content
Hunan Nucien Pharmaceutical Co., Ltd. logo

Hunan Nucien Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 688189 ISIN · CNE100007713 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 689 across all filing types
Latest filing 2026-05-22 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688189

About Hunan Nucien Pharmaceutical Co., Ltd.

http://www.nucien.com

Hunan Nucien Pharmaceutical Co., Ltd. is a pharmaceutical enterprise focused on the research, development, manufacturing, and commercialization of chemical drugs and active pharmaceutical ingredients (APIs). The company operates modern production facilities designed to meet international Good Manufacturing Practice (GMP) standards. Its product portfolio encompasses a wide range of therapeutic categories, including cardiovascular health, anti-infectives, gastrointestinal treatments, and metabolic disorders. Nucien Pharmaceutical integrates advanced synthesis technologies with rigorous quality control systems to supply both domestic and international markets. The organization emphasizes innovation in drug delivery systems and the optimization of manufacturing processes to enhance therapeutic efficacy and patient safety.

Recent filings

Filing Released Lang Actions
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the company’s 2025 Annual General Meeting, detailing each proposal and the vote counts and percentages by shareholder category. This corresponds to a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-22 Chinese
关于控股股东筹划战略重组的提示性公告
Regulatory Filings Classification · 83% confidence The document is a regulatory “提示性公告” in Chinese announcing that the company’s controlling shareholder is preliminarily planning a strategic reorganization. It is not an actual transaction, financial report, earnings release, board change, dividend notice, or proxy solicitation, nor does it contain substantive financial data. It is a general compliance disclosure required by the securities regulator. Therefore it falls under the fallback category of Regulatory Filings (RNS).
2026-05-14 Chinese
南新制药2025年度“提质增效重回报”行动方案评估报告暨2026年度“提质增效重回报”行动方案
Management Reports Classification · 95% confidence The document is titled as an "Action Plan Assessment Report" for 2025 and an "Action Plan" for 2026 by Hunan Nanxin Pharmaceutical Co., Ltd. It discusses detailed operational, strategic, governance, and capital management plans and evaluations. The content includes comprehensive business progress, R&D updates, governance improvements, shareholder return mechanisms including share repurchase plans, and investor communication strategies. The document is lengthy (4377 characters) and contains substantive narrative and data about company operations and plans rather than just an announcement or a brief summary. It is not a typical annual report (10-K) or interim report (IR) with full financial statements, but rather a management-level report focusing on business strategy, operational progress, governance, and outlook. This aligns best with a Management Reports (MDA) filing, which covers management's detailed explanation of financial results, business trends, and outlook. It is not a simple announcement or certification, so it is not RNS or RPA. Therefore, the most appropriate classification is MDA with high confidence.
2026-04-29 Chinese
2025年度利润分配预案公告
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan announcement for the fiscal year 2025 by Hunan Nanxin Pharmaceutical Co., Ltd. It details the company's decision not to distribute cash dividends, not to issue bonus shares, and not to convert capital reserves into shares. The document includes explanations about the company's financial performance, industry context, and strategic considerations. It also mentions the approval by the board of directors and the need for shareholder meeting approval. The document is relatively short (2769 characters) and serves as an announcement of the profit distribution plan rather than a full financial report or annual report. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it fits best into the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and related details for shareholders, including decisions not to pay dividends.
2026-04-29 Chinese
内幕信息知情人管理制度（2026年4月修订）
Governance Information Classification · 95% confidence The document is titled '湖南南新制药股份有限公司内幕信息知情人管理制度' which translates to 'Insider Information Insider Management System of Hunan Nanxin Pharmaceutical Co., Ltd.' It is a detailed internal policy document outlining the management, definition, scope, confidentiality, registration, and penalties related to insider information and insider persons. It references regulatory laws and stock exchange rules, but it is not a financial report, earnings release, or any form of shareholder meeting material. It is a governance-related document detailing internal rules and compliance procedures for insider information management. Therefore, it fits best under Governance Information (CGR). The document length (6539 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2026-04-29 Chinese
华兴会计师事务所（特殊普通合伙）关于前期会计差错更正专项说明的鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed auditor's attestation report issued by Huaxing Certified Public Accountants LLP regarding a special explanation on prior period accounting error corrections for Hunan Nanxin Pharmaceutical Co., Ltd. It references specific accounting standards and regulatory disclosure rules related to accounting policy changes and error corrections. The document includes detailed financial statement adjustments for multiple years (2021-2024) and the auditor's reasonable assurance conclusion on the management's special explanation. It is not a full annual or interim report but a standalone audit-related assurance report focused on accounting error corrections. It is not merely an announcement or certification but contains substantive audit opinion and financial data related to the error corrections. Therefore, it fits the definition of an Audit Report / Information (AR). The document length (8706 characters) and content confirm it is a full report, not just an announcement or certification. Hence, the classification is AR with high confidence.
2026-04-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.